Revance's crosslinked HA filler gains first-line indication for infraorbital volume loss—a new revenue stream for practices.
The FDA has cleared RHA Redensity Eye, Revance's crosslinked hyaluronic acid filler, for correction of undereye hollowing (infraorbital depression). The approval expands the RHA platform beyond its existing facial wrinkle and fold indications, creating a dedicated SKU for a high-demand anatomical zone.
Undereye hollowing is a signature aging marker that drives significant patient volume in aesthetic practices. Until now, practitioners have used off-label applications of standard RHA or other HA fillers in this delicate periorbital region. A cleared indication reduces liability exposure and provides marketing clarity—patients recognize FDA-cleared products as the standard of care.
First FDA-cleared HA filler dedicated to undereye hollowing correction.
The move positions Revance to compete directly in a space where Allergan Aesthetics' Juvéderm and Galderma's Restylane hold established market share. Practices will need to evaluate whether RHA Redensity Eye's rheology and longevity claims justify inventory allocation and pricing strategy in an already-crowded undereye segment.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
